Differential regulation of BACE1 expression by oxidative and nitrosative signals

Young-Don Kwak¹, Ruishan Wang¹, Jing Jing Li¹, Yun-Wu Zhang², Huaxi Xu³, Francesca-Fang Liao¹*

Abstract

Background: It is well established that both cerebral hypoperfusion/stroke and type 2 diabetes are risk factors for Alzheimer’s disease (AD). Recently, the molecular link between ischemia/hypoxia and amyloid precursor protein (APP) processing has begun to be established. However, the role of the key common denominator, namely nitric oxide (NO), in AD is largely unknown. In this study, we investigated redox regulation of BACE1, the rate-limiting enzyme responsible for the β-cleavage of APP to Aβ peptides.

Results: Herein, we studied events such as S-nitrosylation, a covalent modification of cysteine residues by NO, and H2O2-mediated oxidation. We found that NO and H2O2 differentially modulate BACE1 expression and enzymatic activity: NO at low concentrations (<100 nM) suppresses BACE1 transcription as well as its enzymatic activity while at higher levels (0.1-100 μM) NO induces S-nitrosylation of BACE1 which inactivates the enzyme without altering its expression. Moreover, the suppressive effect on BACE1 transcription is mediated by the NO/cGMP-PKG signaling, likely through activated PGC-1α. H2O2 (1-10 μM) induces BACE1 expression via transcriptional activation, resulting in increased enzymatic activity. The differential effects of NO and H2O2 on BACE1 expression and activity are also reflected in their opposing effects on Aβ generation in cultured neurons in a dose-dependent manner. Furthermore, we found that BACE1 is highly S-nitrosylated in normal aging brains while S-nitrosylation is markedly reduced in AD brains.

Conclusion: This study demonstrates for the first time that BACE1 is highly modified by NO via multiple mechanisms: low and high levels of NO suppress BACE1 via transcriptional and post translational regulation, in contrast with the upregulation of BACE1 by H2O2-mediated oxidation. These novel NO-mediated regulatory mechanisms likely protect BACE1 from being further oxidized by excessive oxidative stress, as from H2O2 and peroxynitrite which are known to upregulate BACE1 and activate the enzyme, resulting in excessive cleavage of APP and Aβ generation; they likely represent the crucial house-keeping mechanism for BACE1 expression/activation under physiological conditions.

Background

It is well established that both cerebral hypoperfusion/stroke and type 2 diabetes are risk factors for Alzheimer’s disease (AD) [1-4]. Oxidative and nitrosative stresses are common denominators for these age-related diseases [5]. Oxidative stress is associated with β-amyloid peptide (Aβ) accumulation in the brains of AD patients [6,7]. Aβ is generated by sequential proteolytic cleavages of the transmembrane amyloid precursor protein (APP) by two membrane-bound proteases, β-secretase (BACE1) and the γ-secretase complex composed of presenilin 1 (PS1), nicastrin, APH-1 and PEN-2 [8-10]. In AD brains, the specific regions affected by Aβ deposition correlate with increased BACE1 protein levels and activity [11-15]. Together with the observation that amyloid pathology was diminished in mice deficient in BACE1 [16,17], these findings strongly suggest that BACE1 elevation leads to enhanced Aβ production and deposition in AD. Given the central role of Aβ in AD pathogenesis and the fact that BACE1 is the rate-limiting enzyme in APP processing and Aβ generation, BACE1 remains one of the most important therapeutic targets for treating AD.
Compelling evidence indicates that BACE1 expression is tightly regulated at both the transcriptional and translational levels [18,19]. A number of transcriptional factors have been identified that positively or negatively regulate BACE1 gene expression under both basal and cell-stressed conditions, such as inflammation [20-22]. Some studies suggest that BACE1 is regulated by specific microRNAs, post-translationally [23-25]. In addition to inflammation, other conditions have also been shown capable of causing increased BACE1 expression in the brain, including oxidative stress, traumatic brain injury [26], hypoxia and ischemia [27,28]. Neuronal cells exposed to oxidizing agents such as H2O2 and 4-HNE (4-hydroxynonenal) also show increased BACE1 expression [29,30]. Moreover, injury and stress-induced increases in lipid peroxidation were recently demonstrated to be responsible for upregulation of BACE1 expression in the brain of a genetic mouse model [31]. While the molecular mechanism underlying ischemia/hypoxia-induced BACE1 activation and APP processing has been extensively studied [32-34], the molecular basis of oxidative/nitrosative signal-mediated BACE1 regulation is virtually unknown.

The diffusible gaseous nitric oxide (NO) molecule is generated by activated nitric oxide synthase (NOS) which exists in at least three isoforms (neuronal nNOS, inducible iNOS and endothelial eNOS). NO is known to have pleiotropic physiological and pathological effects depending on the target tissue and cell type [35,36]. For instance, in blood vessels NO functions as a vasodilator, while in the nervous system NO acts as a neurotransmitter. However, if produced in excess and in the appropriate redox state, NO can be neurotoxic. It is well-accepted that NO released from eNOS is protective by promoting vasodilation while NO produced from overactivation of nNOS or iNOS under inflammatory conditions (which generates over 1000-fold more NO compared to constitutive nNOS and eNOS) is deleterious [37,38]. Often, the damage caused by excessive amounts of NO is affected through a neurotoxic derivative named peroxynitrite formed by combining with superoxide anions (O2). Signaling by NO is transduced mainly by targeted modifications of critical cysteine residues in proteins, including S-nitrosylation and S-oxidation, as well as by lipid and tyrosine nitration [39,40]. S-nitrosylation, the covalent modification of a thiol group by NO, probably represents the major mechanism of NO signaling [41-44]; it plays a critical role in fine-tuning a number of important molecules in the CNS related to cell death, protein folding and degradation [45,46]. We recently demonstrated that the PI3K/Akt signaling pathway, which is arguably the most important pro-survival pathway in neurons, is sensitive to this redox regulation; S-nitrosylation and NO-mediated regulation of PTEN represents a novel and crucial mechanism to activate PI3K/Akt signaling [47].

In this study, we investigated NO-mediated regulation of BACE1 and compared it to that of H2O2. We speculated that the dual functions of NO may exert differential effects on BACE1 regulation. Indeed, we observed different effects from NO at low and high levels and found that the two conditions also regulate BACE1 differently from H2O2-mediated oxidation; these may represent the actual redox regulation of BACE1 during the various stages of AD pathogenesis.

Results
Exogenous and endogenous NO donors induce S-nitrosylation of BACE1 in cultured neurons
Using biotin-switch assays [48], we found that S-nitrosylation of BACE1 (SNO-BACE1) can be rapidly induced in primary cultured cortical neurons treated with the physiological NO donor S-nitrosocysteine (SNOC) in a dose-dependent manner. Detectable nitrosylation was induced by 100 nM SNOC with a plateau seen at 100 μM of SNOC. Notably, specific nitrosylation occurred only on the mature form of BACE1 (upper band, Figure 1A). We therefore only present data for the mature BACE1 in most figures and Western blot analyses. This was also confirmed by a more quantitative fluorescent assay (DAN assay, [49]) using purified recombinant BACE1 (data not shown). Additional neurotoxic compounds that induce NO generation, such as ionomycin, also induced robust SNO-BACE1 within minutes (Figure 1B) which lasted for several hours, even after the NO donors were removed from the cultured media. Furthermore, we found that the induced BACE1 nitrosylation was diminished by DTT treatment (1 mM, data not shown).

SNOC displays differential effects on BACE1 protein levels at low and high concentrations
We then examined the effects of SNOC on BACE1 protein levels and surprisingly found that SNOC exerts different effects at low and high concentrations. Specifically, SNOC at lower than 100 nM reduced BACE1 expression by ~ 50% (Figure 2A) which was restored to normal basal levels at SNOC concentrations higher than 100 nM. Interestingly, SNOC at concentrations higher than 100 nM exerted no effect on BACE1 protein expression levels (Figure 2B). The endogenous NO induced by ionomycin showed no effect on BACE1 at various concentrations (Figure 2C). In contrast, H2O2 induced BACE1 expression at concentrations as low as 10 μM in a dose-dependent manner (Figure 2D).

Low NO levels suppress BACE1 transcription which is likely mediated through cGMP-PKG-upregulated PGC-1alpha
It was previously shown that oxidative stressors such as H2O2 can upregulate BACE1 at the transcriptional level.
To investigate the possibility that the low-concentration NO-mediated BACE1 suppression is effected through transcriptional inhibition, we conducted quantitative RT-PCR on endogenous BACE1 in rat primary neurons treated with various concentrations of SNOC. We found that the BACE1 messages were reduced in a dose-dependent manner from 0.1-100 nM and then slowly restored from 1-100 μM to their basal levels (Figure 3A). The maximum reduction of BACE1 messages was 2-fold, seen between 10-100 nM, which was consistent with the 50% reduction in BACE1 protein levels. We therefore believe that the low-concentration NO-mediated BACE1 suppression is mainly effected through transcriptional regulation.

Since NO signaling at low NO concentration is usually mediated by the classic cGMP activated PKG pathway, we then tested the effect of a potent NO/cGMP-PKG inhibitor, 1H-[1.2.4]Oxadiazolo[4,3-a]quinolin-1-one (ODG), and showed that it abolished the suppressive effect of low NO on BACE1 transcription (Figure 3B). Furthermore, we tested the potential role of the coactivator of PPARγ, named PGC-1α, which is known to be upregulated by low-concentration NO-cGMP signals.
In parallel with BACE1 transcription, we examined the mRNA levels of PGC-1α under various SNOC concentrations and found an inverse correlation between the mRNA levels of BACE1 and PGC-1α (Figure 3C). Because PPARγ has been suggested to suppress BACE1 via its responsive element (PPRE, [53]), it is possible that the upregulated PGC-1α is involved in BACE1 transcriptional control. Indeed, we show here that over-expression of PGC-1α may be the major factor mediating the BACE1 suppression in response to cGMP-PKG signaling.

SNOC and H2O2 have opposing effects on BACE1 enzymatic activity and subsequent Aβ generation

Since S-nitrosylation occurs at critical Cys residues which often leads to alteration of the structure and function of the target proteins, we examined BACE1 enzymatic activity upon SNOC and H2O2 treatments. Interestingly, SNOC-BACE1 shows reduced enzymatic activity while oxidized BACE1 exhibits enhanced activity; assays were performed with a commercial kit using both cell lysates and purified recombinant protein (Figure 4A). Accordingly, SNOC and H2O2 display opposite effects on Aβ generation, as determined by IP-Westerns using an antibody specific to Aβ (6E10). Consistent with the dose-dependent effects of H2O2 on BACE1 transcription, H2O2 also shows an effect dependent on the same dosages that induce BACE1 and Aβ generation, with a maximum effect seen at 10 μM (Figure 4B).

SNO-BACE1 levels decrease in late stage AD brains which inversely correlates with BACE1 protein levels

We next investigated whether S-nitrosylation of BACE1 occurred in vivo in neurodegenerative disorders associated with high levels of nitrosative stress, such as stroke and AD. We included in our tests those specimens taken from autopsy patients diagnosed at an early stage of AD called mild cognitive impairment (MCI) and compared them to age-matched control brain specimens (i.e., patients died from disorders not related to CNS). We chose to examine the entorhinal cortices, the most vulnerable region in AD brains. The patient cohort and information are summarized in the additional table. From semi-quantitative profiling of SNO-BACE1 and total BACE1 in 18 human brains, we found that SNO-BACE1 was at high levels in control and MCI samples and was markedly reduced in the late stage AD brains (Figure 5).

Discussion

It is widely accepted that oxidative stress is one of the earliest changes that occurs in the pathogenesis of AD, arising from the imbalance between increased production of reactive oxygen and nitrogen species and impaired antioxidant defenses, as reflected in the
accumulation of oxidative damage to macromolecules detected in MCI and AD brains [39,40]. In this work, we present in vitro and in vivo evidence of NO-mediated regulation of BACE1. We are the first to demonstrate that NO, at different levels, can exert differential regulation on BACE1: at low levels, NO suppresses BACE1 transcription while at modest to high levels, NO induces S-nitrosylation of BACE1 and inactivates the enzyme. Furthermore, we show that S-nitrosylation of BACE1 occurs in normal aging and MCI brains but is significantly diminished in late stage AD brains. Given the central role of Aβ in AD pathogenesis and the fact that BACE1 is the rate-limiting enzyme in APP processing and Aβ generation, the redox regulation of BACE1 identified herein may represent a novel and crucial mechanism for keeping BACE1 at physiological levels/activity.

The multifaceted actions of the NO group can be classified into two categories: classic NO-mediated/cGMP-dependent actions and reactive nitrogen species-mediated/cGMP-independent actions. The cGMP-dependent actions often play critical roles in a variety of physiological processes, including NO-mediated vasodilation. In contrast, cGMP-independent actions are more frequently postulated to be involved in the pathological responses which are primarily effected by nitrosative post-translational modifications of proteins such as S-nitrosylation and tyrosine nitration [41-46]. Although low nanomolar concentrations of NO donors are sufficient to elicit cGMP-dependent signals, 50-100 μM of NO donors is required for S-nitrosylation-mediated alterations of protein function in cultured cells [37,38,54].

Based on these ideas, we speculate that the NO generated by different NOs exerts differential modifications of BACE1. For example, the low levels of NO that result in suppression of BACE1 transcription may represent the NO released from vascular eNOS. Although it is difficult to measure the precise concentration of the bioreactive NO in the blood circulation of a healthy vertebrate, the decreased BACE1 transcription induced at the 10-100 nM range of NO donors may be related to the protective actions caused by the release of NO from vascular eNOS. In fact, this is collaboratively by the recent finding that BACE1 expression was elevated in mice deficient in eNOS [55]. Our data also suggest that PGC-1α, a crucial PPARγ coactivator in the transcriptional controls of gluconeogenesis and energy metabolism [56], may be the key factor executing the effects of low NO, through the activated cGMP-PKG signaling pathway. Since PGC-1α is the most critical regulator in response to metabolic stress, it is believed to play a key role in AD pathogenesis. Our finding that PGC-1α is likely involved in BACE1 transcriptional control provides the first molecular basis of a metabolic signal/factor regulating an AD gene. In support of this, PGC-1α expression was found to be reduced in AD brains [57] and it was recently reported that PGC-1α facilitates BACE1 protein degradation via the UPS [58,59]. Further characterization of the transcriptional network involving PGC-1α, directly or indirectly, on BACE1 promoter, will draw a fuller picture of the metabolic factors regulating AD genes, which likely involve the entire AMPK-SIRT1-PGC-1α pathway, in which NO signaling plays an important role.

On the other hand, the high levels of NO-mediated BACE1 inactivation via post-translational modification in cultured neurons likely reflects the NO generated by iNOS, known to elicit much higher NO production (over 1,000-fold) compared with that generated by the constitutive NOs [37,38]. Inducible iNOS, shown to be involved in the pathogenesis of AD, is activated under inflammatory conditions and may upregulate BACE1 as a result of activated NF-κB and toxic peroxynitrite formed by NO and superoxide anions. Although we show that SNO-BACE1 is associated with reduced enzymatic activity, the elevated protein expression and enzymatic activity of BACE1 in late stages of AD may reflect the dominant effect of severe oxidation by H2O2 and peroxynitrite; it has been shown previously that lipid oxidative products, such as 4-HNE, can upregulate BACE1 transcriptionally [30].

H2O2-induced modification and S-nitrosylation represent the two dominant oxidative events modifying critical Cys residues in proteins. Interestingly, we observed opposite effects from these two oxidative modifications modifying critical Cys residues in proteins. Among the 11 Cys residues on BACE1, it is known that six Cys residues form three pairs of intramolecular disulfide bonds in mature BACE1 (Cys216-420, Cys278-443 and Cys330-380; Figure 6A) which is essential for its membrane-association and protein maturation but is not required for its enzymatic activity [60]. Since the pattern of BACE1 S-nitrosylation shows that it occurs predominantly on the mature form of BACE1 (Figure 1A), we reason that the three pairs of Cys in the enzymatic pocket are not likely sites for nitrosylation. Indeed, our preliminary study used site-directed mutagenesis to analyze individual BACE1 mutants with each Cys mutated to Ala and showed that Cys mutation at the positions 216, 278, 330, 380, 420, 443, or 466 (the membrane-proximal ones) resulted in lack of mature

Page 5 of 10

Kwak et al. Molecular Neurodegeneration 2011, 6:17
http://www.molecularneurodegeneration.com/content/6/1/17
BACE1 proteins (Figure 6A). Substitution of each of the four Cys residues in the cytoplasmic tails, which are also the S-palmitoylation sites, had different results; the C483A mutant abolished mature BACE1, making it difficult to assess its contribution as a nitrosylation site; Cys478A and Cys482A mutants appeared to show reduced BACE1 nitrosylation and likely represent S-nitrosylation sites under physiological conditions. It should be pointed out that the results of this type of semi-quantitative analysis are not sufficient to determine the molecular basis of nitrosylation sites unambiguously. In particular, the cytoplasmic tail has been reported to be non-essential for the enzymatic activity of BACE1 [61,62], it remains unclear how the nitrosylation affects BACE1 activity. Additional research to determine the molecular basis of the nitrosylation and oxidation events by quantitative mass spectrometry, as well as further analysis of BACE1 and subcellular trafficking, localization and distribution in lipid rafts using cell biology approaches, are necessary to clarify the mechanism.

Conclusion
In summary, our studies have demonstrated that NO exerts differential regulation on BACE1 at low and modest to high concentrations, suppressing BACE1 transcriptionally or post-translationally through S-nitrosylation, respectively. S-nitrosylation may represent a basic regulatory mechanism for maintaining BACE1 at physiological levels, outside of events that challenge the brain with a wave of high oxidative stressors which upregulates and activates BACE1. As BACE1 represents a favored therapeutic target for developing anti-AD agents, pharmacological inhibitors of BACE1 have been actively pursued for more than a decade. Despite significant progress, the development of specific cell-permeable drugs that penetrate into the brain remains a challenge. Due to the recent discouraging results from Eli Lilly’s trials on a γ-secretase inhibitor (Semagacestat/LY450139) showing worsening cognitive performance in AD patients, efforts to discover a novel mechanism to modulate secretases is of particular importance. Further validation of the redox regulatory mechanism of BACE1 may provide novel leads to modulate BACE1 by selectively targeting oxidized BACE1.

Methods
Cell culture, treatment of neurotoxic reagents and transfection
Primary cultured cortical neurons (PRCN), neuroblastoma N2a cells and HEK 293 cells were prepared as described [63]. N2a cells stably transfected with human

Figure 6 Mapping crucial cysteine residues for SNO-BACE1. (A) Schematic diagram of BACE1. BACE1 is a 501 amino-acid transmembrane protein. Signal peptide (1-21 aa) and pro-peptide (22-45 aa) are cleaved during protein maturation. Within the lumenal domain there are two active site motifs (signature sequences of aspartyl proteases) situated at amino acids 93-96 and 289-292, four N-glycosylation sites and six cysteine residues involved in intramolecular disulfide bonds. The transmembrane domain is located between amino acids 461 and 477, and the C-terminal part of the protein (24 aa) is located in the cytosol. (B) Site-directed mutagenesis data on the Cys mutants of BACE1. SNO-BACE1 levels were determined by biotin-switch assays and data were analyzed by densitometry of the SNO-BACE1/total BACE1 ratio to identify crucial cysteine residues for s-nitrosylation of BACE1. Wild type and mutants of BACE1-HA expression plasmids were transfected into HEK293 cells. After biotin-switch assay, SNO-BACE1 and total BACE1 proteins were probed with an anti-HA antibody.
APP695 (N2a695 cells) were maintained in N2a culture media supplemented with 400 µg/mL G418 (Sigma). For the majority of experiments, freshly prepared SNOC (Sigma-Aldrich, St. Louis, MO) was added at 100-200 µM to these cells for 30 or 60 min. SNOC was freshly prepared as described [54]. In brief, to prepare a 100 mM stock solution, 0.0069 g sodium nitrite and 0.0121 g l-cysteine were added to 950 µl H2O. Then, 50 µl of 10N HCl is added to adjust pH to 7.4. For Aβ25-35 peptides (Bachem, Torrance, CA), neurons were treated for 4 hours before cell lysates were prepared. Transient transfections were performed with plasmid constructs for pCMV-HA-BACE1-WT and its site-directed mutated constructs (Cysteine to Alanine substitution) according to manufacturer’s protocol.

**Human patient brains**

Human brain samples were provided by UCSD, San Diego, CA and were analyzed with institutional permission under California and National Institutes of Health guidelines [Additional file 1]. Informed consent was obtained following the procedures of the Institutional Review Boards of the Sanford-Burnham Institute for Medical Research.

**Biotin-switch assay for detection of BACE1 S-nitrosylation**

A biotin switch assay for detection of SNO-BACE1 was performed as previously described with minor modifications [48]. PRCN, N2a or HEK293 cells were exposed to various concentrations (0.01, 0.1, 10, 50, 100, 200 and 400 µM) of SNOC for 30 min. For calcium ionophore (ionomycin), 1 µM of ionomycin was applied for 0-5-10-15-30 min to neuronal cells.

**Western blot analysis**

SDS-PAGE gels and Western blots were performed as described [64]. Samples were run on 10-20% Tricine gels (Invitrogen) for Aβ peptides and 4-20% Tris-Glycine gels (Invitrogen) for regular SDS-PAGE analysis. The following antibodies (Abs) were used in the present study: mouse anti-HA Ab (Sigma); mouse anti-α-tubulin Ab (Sigma, St. Louis, MO, USA); mouse anti-β-actin Ab (Sigma); anti-mouse IgG and anti-rabbit IgG horseradish peroxidase-conjugated Abs (Chemicon, Temecula, CA, USA). In most of the experiments performed in the early stages, we used the guinea pig antibody GP45 (Convance, Inc). Recently, we repeated some key experiments with a specific monoclonal antibody (5D3) derived from BACE1 deficient mice [9].

**Fluorogenic BACE 1 activity assay**

This assay was performed according to the company’s protocol [64]. Briefly, cultured PRCN, N2a and HEK293 cells were treated with or without SNOC and H2O2 for the indicated time periods and homogenized. The resulting aliquots (containing 15 µg of proteins) were centrifuged at 13 000 × g for 15 min. Then, the membrane pellets were recovered and incubated at 37°C for 30 min in 50 µl of assay reaction buffer (50 mM sodium acetate, pH 4.5; for α-secretase, 10 mM Tris-HCl, pH 7.5) containing 10 µM specific fluorogenic substrates. After incubation, fluorescence was measured using a spectrometer at excitation/emission wavelengths of 320/420 nm for BACE-1.

**Aβ assays**

Following various treatments, serum-free media was conditioned for 4 hrs. Aliquots of conditioned media were immunoprecipitated with 6E10 antibody and protein G/A beads to measure Aβ peptides [65].

**Quantitative RT-PCR on BACE1 and PGC-1 Messages**

Total RNA was extracted using TRIzol reagent (Invitrogen). SuperScript First-Strand kit (Invitrogen) was used to synthesize the first strand cDNA from samples with an equal amount of RNA, according to the manufacturer’s instructions. Synthesized cDNAs were amplified using RealMasterMix SYBR ROX (5 Prime) and Mastercycler ep from Eppendorf with 3 min pre-incubation at 95°C followed by 40 cycles of 30 s at 95°C, 30 s at 55°C, 30 s at 72°C. The data were analyzed by using realplex. PCR products were verified by melting curve analysis and agarose gel electrophoresis. Rat bace1 primers [forward 5’-TGGGTGAAGTCACCAATCAG-3’ and reverse 5’-CAGCAATCTGAGGATTGTGCT-3’], human bace1 primers [forward 5’-GCAAGCCCTACTACGTAAGAGA-3’ and reverse 5’-GATATCCACGGATTTGAGAC-3’], and rat pgc-1α primers [forward 5’-AAAGGCCCCAAG CAGAGA-3’ and reverse 5’-GTAATACCAACAGGCGCTCTT-3’] were used in the present studies. Primers used for rat GAPDH, forward 5’-ACATTTGGCCAT CAACGAC-3’, reverse 5’- CCTGCCGCTGTTAGC GT CAT-3’; human GAPDH primers, forward 5’- AATCC CATCACCATCTTCC-3’ and reverse 5’- GGACTCCACGG CGCTCTT-3’ were used in the present studies. Levels were normalized with the levels of GAPDH.

**Luciferase assay for BACE1 promoter activity**

1.5 Kb rat BACE1 promoter [63] and 2.2 Kb human BACE1 promoter [19] in pGL3-Basic vector, together with PGC-1α expression vector (Addgene), were transfected into HEK 293 cells. pRL-SV40 containing the Renilla luciferase gene (Promega) was cotransfected as an internal control. 24 hours after transfection, cells were collected in passive lysis buffer and analyzed with the Dual luciferase reporter system (Promega) following the manufacturer’s instructions.
Site-directed mutagenesis of BACE1

BACE1 mutants were created by site-directed mutagenesis (QuickChange® II Site-Directed Mutagenesis Kits, Stratagene, La Jolla, USA) at C216, C278, C330, C380, C420, C443, C466, C474, C478, C482, and C485 residues. The primers for C216A forward 5'-CTCTTGGCTGCTTTGCCACCC-3' and reverse 5'-GGGAAAGGAGAACCAACAGTCGTCGAGGC-3'; C278A forward 5'-CTGAAAATATGGAGCCGAGGAAGAT-3' and reverse 5'-GTGTTACTCCTGTTGCTC-3'; C330A forward 5'-GAGCAAGCTGCTGAGCAGGCC-3' and reverse 5'-GCCTGCTTGCAGCCACCAGGCTC-3'; C380A forward 5'-GTCCCAAGAGGAAGTTGCTGC-3' and reverse 5'-GGCAATTTCAGATCGAGCTGTC-3'; C420A forward 5'-GTGTCAGGCTGCCATGTCAGATG-3' and reverse 5'-CATCGTCGACATGCGGCGGGG-3'; C443A forward 5'-GACATGGAAGAGCTGCTACAATTCT-3' and reverse 5'-GAATGGTCTAGACCAGCTGTCCTCAGATGTC-3'; C466A forward 5'-CATGGCTGCCATCGCCACCAGGCCCTCTCATG-3' and reverse 5'-CATGGAAGGACCAACAGTGGCCTCGACGAGG-3'; C474A forward 5'-CATGTCGCCACTGCGGACCGACCTGTCGACT-3' and reverse 5'-CTGCTGGCGCGCCGCCGGCCGACGAGG-3'; C478A forward 5'-CATGGCTGCCATCGCCACCAGGCCTCTCATG-3' and reverse 5'-CATGGAAGGACCAACAGTGGCCTCGACGAGG-3'; C482A forward 5'-CATGTCGCCACTGCGGACCGACCTGTCGACT-3' and reverse 5'-CTGCTGGCGCGCCGCCGGCCGACGAGG-3'; C485A forward 5'-CATGGCTGCCATCGCCACCAGGCCTCTCATG-3' and reverse 5'-CATGGAAGGACCAACAGTGGCCTCGACGAGG-3'.

Statistics

All quantitative data were presented as means ± SDV. Comparisons between groups were analyzed with unpaired ANOVA using Graphpad PRIZM software (La Jolla, CA, USA) and values of p < 0.05 were considered to be significant.

Additional material

Additional file 1: The table of the patient cohort and information

Acknowledgements

We thank Drs. Eliezer Masliah for providing human brain specimen, Robert Vassar for providing precious anti-BACE1 antibody (SD3) and Jianlin Lin for pcDNA-PCClin plasmid. This work was partially supported by the NIH grants (R01 NS054480, AG031893 to F-F. L.; R01 AG021173, R01 NS046673 and R01 AG030197 to H.X.), the grants from the Alzheimer’s Association (to Y-W Z, H. X. and F.F.L.), and the American Health Assistance Foundation (to H.X.). Y-D K was the recipient of 2008 Young Scholar Award from Alzheimer’s association San Diego/Imperial Chapter.

Author details

1Department of Pharmacology, University of Tennessee Health Science Center, College of Medicine, 874 Union Avenue, Memphis TN, 38163, USA.
2Institute for Biomedical Research and Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Xiamen University, Xiamen 361005, China. 3Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, 10190 North Torrey Pines Road, La Jolla, CA 92037, USA.

References

1. Cechetto DF, Hachinski V, Whitehead SN: Vascular risk factors and Alzheimer’s disease. Expert Rev Neurother 2008, 8:743-750. Review.
2. Punnell C, Gao S, Callahan CM, Hendrie HC: Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 2009, 23:1-10, Review.
3. Janson J, Laedtke T, Parisi JE, O’brien P, Petersen RC, Butler PC: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
4. Biesels GJ, Kappelle LJ: Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 2005, 33:1041-1044.
5. Reddy VP, Zhu X, Perry G, Smith MA: Oxidative stress in diabetes and Alzheimer’s disease. J Alzheimers Dis 2009, 6:763-774, Review.
6. Lovett MA, Markesbery WR: Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer’s disease. Nucleic Acids Res 2007, 35:7497-7504.
7. Sultana R, Perluigi M, Butterfield DA: Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of beta in pathogenesis, Acta Neuropathol 2009, 118:131-150, Review.
8. Vetrivel KS, ZhangYW, Xu H, Thinaikan G: Pathological and physiological functions of presenilins. Mol Neurodegener 2008, 1:4.
9. Cole SL, Vassar R: The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007, 2:22.
10. ZhangYW, Xu H: Molecular and cellular mechanisms for Alzheimer’s disease: understanding APP metabolism. Curr Mol Med 2007, 7:687-696, Review.
11. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC: Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002, 59:1381-1389.
12. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ: Alpha- and beta-secretase: profound changes in Alzheimer disease. Biochem Biophys Res Comm 2002, 299:373-376.
13. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G: Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 2002, 51:783-786.
14. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y: Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
15. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y: Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA 2004, 101:3632-3637.
16. LuoY, Bolon B, Kahn S, Bennett BD, Babu-Khan Sm Denis P, Pan W, Kha H, Zhang J, Gong J, Martin L, Locs J, Yan Q, Richards WG, Citron M, Vassar R: Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished ab-amylloid generation. Nature Neurosci 2001, 4:251-252.
17. Roberts RS, Anderson J, Bass G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawa TT, Kola I, Kola I, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoar M, Shopp GM, Shuck M, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wiisam J, Wright S, McConlogue L: BACE knockout mice are healthy albeit lacking the primary b-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet 2001, 10:1317-1324.
37. Drew B, Leeuwenburgh C: The emerging multifaceted roles of nitric oxide.
33. Zhang X, Zhou K, Wang R, Cui K, Lipton SA, Liao FF, Xu H, Zhang YW:
32. Sun X, Wang Y, Qin H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang X, Zhang S, Liu X, Song W: Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 2005, 19:739-749.
27. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW:
31. Chen L, Na R, Gu M, Richardson A, Ran Q:
30. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, MiR-107 is reduced in Alzheimer species. Ann Surg 2004, 5620-625.
19. Rossner S, Sastre M, Bourne K, Lichtenhalter S: Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog Neurobiol 2006, 79:95-111.
20. Christensen MA, Zhou W, Qin H, Lehman A, Philippen S, Song W: Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 2004, 24:685-687.
21. Sun X, Wang Y, Qin H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang X, Zhang S, Liu X, Song W: Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 2005, 19:739-749.
22. Ge YW, Maloney B, Sambamurti K, Lahiri DK: Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J 2004, 18:1937-1039.
23. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Qingou I, Nelson PT: The expression of microRNA miR-107 early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008, 28:1213-1223.
24. Helbert SS, Horike K, Nicola L, Papadopoulos AS, Mandemakers W, Slihaartogou AN, Kauppinen S, Delacourte A, De Strooper B: Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008, 105:6415-6420.
25. Nelson PT, Wang WX: MiR-107 is reduced in Alzheimer's disease brain neocortical validation study. J Alzheimer's Dis 2010, 21:75-79.
26. Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schieibs R: Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neurotrauma 2011, 11523-536.
27. Wen Y, Onyewuchche G, Yang S, Liu R, Simpkins JW: Increased beta-secretase activity and expression in rats following total cerebral ischemia. Brain Res 2004, 10091-1.
28. Tesco G, Koh YH, Yang J, Canonical AN, Das S, Sena-Esteves M, Perry G, Tamagno E, Santoro G, Davit A, Danni O, Smith MA, Hiltunen M, BACE1 expression and beta-amyloid generation. J Neurochem 2004, 1037-1056.
29. Tamagno E, Bardini P, Obibbi A, Vitali A, Borigli R, Zacheo D, Orzanato MA, Danni O, Smith MA, Perry G, Tabaton M: Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002, 10:279-288.
30. Tamagno E, Farala M, Bardini P, Piccini A, Borigli R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M: Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinase pathways. J Neurochem 2005, 92:628-636.
31. Chen L, Na R, Gu M, Richardson A, Ran Q: Lipoic peroxidase up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem 2008, 107:197-207.
32. Sun X, He G, Qin H, Zhou W, Debeli F, Cai F, Staufenbiel M, Huang LE, Song W: Hpo/Hif1alpha facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006, 103:18727-18732.
33. Zhang X, Zhou K, Wang R, Cai K, Lipton SA, Liao FF, Xu H, Zhang YW: Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007, 282:10873-10880.
34. Guglielmotto M, Aragon M, Autelli R, Glibberto L, Novo E, Colombato S, Danni O, Parola M, Smith MA, Perry G, Tamagno E, Tabaton M: The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 2009, 108:1045-1056.
35. Breit D, Frieder SH: Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 1994, 63:175-195. Review.
36. Kuo PC, Schroeder RA: The emerging multifaceted roles of nitric oxide. Ann Surg 1995, 221:220-223.
37. Drew B, Leeuwenburgh C: Aging and the role of reactive nitrogen species. Ann N Y Acad Sci 2002, 959:66-61.
62. Vetrivel KS, Meckler X, Chen Y, Nguyen P, Seidah NG, Vassar R, Wong PC, Fukata M, Kounnas MZ, Thinakaran G. Alzheimer disease Aβ production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. *J Biol Chem* 2009, 284:3793-3803.

63. Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H, Liao FF. Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. *J Neurosci* 2009, 29:11226-11236.

64. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. Antidiabetic drug metformin (Glucophage®) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. *Proc Natl Acad Sci USA* 2009, 106:3907-3912.

65. Huang X, Chen Y, Li WB, Cohen SN, Liao FF, Li L, Xu H, Zhang YW. The Rps23rg gene family originated through retroposition of the ribosomal protein S23 mRNA and encodes proteins that decrease Alzheimer’s beta-amyloid level and tau phosphorylation. *Hum Mol Genet* 2010, 19:3935-3943.

doi:10.1186/1750-1326-6-17

Cite this article as: Kwak et al.: Differential regulation of BACE1 expression by oxidative and nitrosative signals. *Molecular Neurodegeneration* 2011 6:17.